Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer

Ovarian cancer treatment: The end of empiricism?

(2015) Stephanie Lheureux et al.   CANCER

Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research

(2015) Kevin M. Elias et al.   GYNECOLOGIC ONCOLOGY

Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives

(2015) K. Matsumoto et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells

(2015) N Mohell et al.   Cell Death & Disease

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers

(2015) Brandon-Luke L. Seagle et al.   Oncotarget

Predicting survival in head and neck squamous cell carcinoma from TP53 mutation

(2014) David L. Masica et al.   HUMAN GENETICS

Staging classification for cancer of the ovary, fallopian tube, and peritoneum

(2013) Jaime Prat et al.   INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer

(2013) Pavla Brachova et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Role of Glutathione in Cancer Progression and Chemoresistance

(2013) Nicola Traverso et al.   Oxidative Medicine and Cellular Longevity

Precursors and pathogenesis of ovarian carcinoma

(2013) D. Lim et al.   PATHOLOGY

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

(2013) X Peng et al.   Cell Death & Disease

Evaluating cell lines as tumour models by comparison of genomic profiles

(2013) Silvia Domcke et al.   Nature Communications

PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation

(2013) Noriko Kobayashi et al.   Journal of Ovarian Research

P53 and its molecular basis to chemoresistance in breast cancer

(2012) Stian Knappskog et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile

(2011) Ardian Latifi et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Ovarian Cancer Development and Metastasis

(2010) Ernst Lengyel   AMERICAN JOURNAL OF PATHOLOGY

Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?

(2010) Christopher G. Przybycin et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

(2010) Yves Pommier et al.   CHEMISTRY & BIOLOGY

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

(2010) Ahmed Ashour Ahmed et al.   JOURNAL OF PATHOLOGY

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Blinded by the Light: The Growing Complexity of p53

(2009) Karen H. Vousden et al.   CELL

Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis

(2009) J M R Lambert et al.   ONCOGENE

The fluorometric microculture cytotoxicity assay

(2008) Elin Lindhagen et al.   Nature Protocols

PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2

(2008) J Shen et al.   ONCOGENE